rgd

RGD Trifluoroacetate is a tripeptide that effectively triggers cell adhesion, targets specific cell lines, and elicits particular cell responses by binding to integrins. It is the most effective and frequently used peptide sequence for stimulated cell adhesion on synthetic surfaces. Among the 24 integrins that bind to ECM molecules in an RGD-dependent manner are α3β1, α5β1, α8β1, αIIbβ3, αvβ1, αvβ3, αvβ5, αvβ6, αvβ8, and to some extent α2β1 and α4β1.

RGD peptide (GRGDNP) (TFA) promote apoptosis through activation of conformation changes that enhance pro-caspase-3 activation and autoprocessing.

RGD peptide (GRGDNP) TFA functions as an inhibitor of integrin-ligand interactions, competitively blocking α5β1's interaction with the extracellular matrix (ECM). It induces apoptosis by triggering conformational changes that facilitate pro-caspase-3 activation and autoprocessing. Furthermore, RGD peptide (GRGDNP) TFA is critical in regulating cell adhesion, migration, growth, and differentiation [1] [2] [3].

RGD-Targeted Proapoptotic Peptide is a peptide that preferentially binds to integrins at sites of tumor angiogenesis through its C-terminal RGD-4C sequence (ACDCRGDCFC).

RGD-4C, an arginine-glycine-aspartic acid peptide (ACDCRGDCFC), exhibits integrin binding activity. The primary integrin recognition site in extracellular matrix proteins, the Arg-Gly-Asp (RGD) sequence, allows peptides with this sequence to mimic matrix proteins' recognition specificity. As an αv-integrin ligand, RGD-4C can be conjugated with bioactive molecules to demonstrate antitumor effects in animal models [1] [2] [3].

Arg-Gly-Asp TFA (99896-85-2(free base)) (RGD Trifluoroacetate) is a tripeptide that effectively triggers cell adhesion, addresses certain cell lines and elicits specific cell responses; binds to integrins.

Arginine-glycine-aspartic acid

H-Gly-Arg-Gly-Asp-Asn-Pro-OH (GRGDNP) is a integrin-ligand interactions inhibitor.

CGGRGD acetate is a RGD derivative with cysteine as the n-terminal. CGGRGD was synthesized by solid phase peptide synthesis technology, and amino2-cyanobenzothiazole (2-cyanobenzothiazole) (2-cyanobenzothiazole (CBT) was added on the surface of PCL fiber

GRGDSP acetate(91037-75-1 free base) is a synthetic linear RGD peptide and is an integrin inhibitor.

YRGDS Fibronectin Fragment acetate (YRGDS Fibronectin Fragment acetate (134282-68-1 free base))(134282-68-1 free base) is a fibronectin fragment acetate, an adhesion peptide that displays strong binding affinity to thrombin-stimulated platelets. It is RGD consisting of sequence.

GRGDSPK acetate shows inhibitory activity against integrin-fibronectin binding and can be used in research on integrins in bone formation and resorption.

GRGDSPC acetate (GRGDSPC acetate (91575-26-7 free base)) is a 7-amino acid peptide of thiolated cell adhesion.

Cyclo(-RGDyC)acetate is an integrin avb3-affine polypeptide, a circular RGDyc sequence. 

Cyclo(-RGDfC)acetate is an integrin avb3-affine polypeptide, a circular RGDfc sequence.

Cyclo(RGDyK) is a potent and selective αVβ3 integrin inhibitor with an IC50 of 20 nM.

GRGDSPK (EMD 56574) is an inhibitory peptide for RGD-mediated adhesion between integrin and extracellular matrix molecules.

Cyclo(-RGDfK) is a selective αvβ3 integrin inhibitor(IC50 : 0.94 nM).

Cyclo(-RGDfK) (Cyclo (-RGDfK)) is an effective and specific αvβ3 integrin inhibitor.

Cyclo(RGDyK) trifluoroacetate is a potent and selective αVβ3 integrin inhibitor with an IC50 of 20 nM.

iRGD peptide (c(CRGDKGPDC)) is a 9-amino acid cyclic peptide (sequence: CRGDKGPDC) and a molecular mimicry agent that was originally identified in an in vivo screening of phage display libraries in tumor-bearing mice.

LXW7 is an octamer disulfide cyclic peptide and αvβ3 integrin ligand, acts as a potent and specific endothelial progenitor cells (EPCs) and endothelial cells (ECs) targeting ligand. LXW7 is a disulfide cyclic octa-peptide (cGRGDdvc) containing unnatural amino acids flanking both sides of the main functional motif.

Arg-Gly-Glu-Ser acetate is a RGD related peptide that is a control for the RGDS activity of fibrinogen binding to activated platelets.

This is a fibronectin fragment, an adhesion peptide that displays strong binding affinity to thrombin-stimulated platelets. It is RGD consisting of sequence.

Gly-Arg-Gly-Asp-Ser-Pro (GRGDSP) is used as a soluble integrin-blocking RGD-based peptide.

GRGDSPK TFA (EMD 56574 TFA) is a peptide containing the Arg-Gly-Asp (RGD) sequence, serving as a competitive and reversible inhibitor of integrin-fibronectin binding. This compound is utilized in research to elucidate integrins' involvement in bone formation and resorption [1] [2].

CGGRGD is a RGD derivative with cysteine as the n-terminal. CGGRGD was synthesized by solid phase peptide synthesis technology, and amino2-cyanobenzothiazole (2-cyanobenzothiazole) (2-cyanobenzothiazole (CBT) was added on the surface of PCL fiber for ammo

iRGD Peptide 1 TFA is a prototypic tumor-homing peptide with tissue-penetrating capabilities, facilitating deep delivery of therapeutic agents into extravascular tumor tissue. Additionally, it possesses anti-metastatic activity [1].

Cyclo(RGDfK(Mal)), a pentapeptide, enhances the attachment and infiltration of human pluripotent stem cells and is utilized in three-dimensional stem cell culture and expansion [1].

CGGRGD TFA is synthesized via solid-phase peptide synthesis technique and the surface of PCL fibers is aminolysised by amino 2-cyanobenzothiazole followed by the addition of 2-cyanobenzothiazole (CBT)[1].

GRGDSP (TFA) is an integrin inhibitor.

cRGDfK-thioacetyl ester, a bioactive polypeptide, exhibits selective affinity for integrins and can modify near-infrared (NIR) fluorescent probes for targeted cancer imaging [1] [2].

RGDT, a synthetic peptide, is utilized in cancer research [1] [2].

Cyclo(RGDyC), a cyclic pentapeptide, exhibits anti-angiogenic properties and has been investigated in conjunction with liposomal delivery systems for the study of ocular neovascular diseases and cancer [1] [2].

GRGDSPC, a 7-amino acid thiolated cell adhesion peptide, serves as an ideal novel targeted non-viral gene delivery vector due to its ease of synthesis, high efficiency, and low cytotoxicity.

RGDV functions as a platelet aggregation inhibitor and disrupts platelet-dependent thrombus formation. Additionally, it serves in tumor recognition due to its targeting effect [1] [2].

E(c(RGDfK)) is an αvβ3 integrin-specific binding moiety with tumor-targeting properties, demonstrating increased uptake in human ovarian cancer OVCAR-3 xenograft tumors, suggesting potential utility in cancer research [1].

Cyclo(RADfK) is a selective α(v)β(3) integrin ligand extensively used for research, therapy, and diagnosis of neoangiogenesis. It also serves as a negative control for cyclo(-RGDfK-), the RGD peptide, which modulates cell adhesion and is recognized by several integrin family members.

Risuteganib is a synthetic RGD (arginyl-glycyl-aspartic acid)-class peptide that regulates the functions of multiple integrin isoforms.

LXW7 TFA, a cyclic peptide encompassing Arg-Gly-Asp (RGD), serves as an inhibitor of integrin αvβ3. It demonstrates high binding affinity towards αvβ3 integrin, evidenced by an IC50 value of 0.68 μM. Additionally, LXW7 TFA promotes the phosphorylation of VEGFR-2 and the activation of ERK1/2, contributing to its anti-inflammatory effects [1] [2] [3].

Cyclo(Gly-Arg-Gly-Asp-Ser-Pro) (c(GRGDSP)) is an RGD-containing inhibitory peptide and synthetic α5β1 integrin ligand that competitively inhibits the binding of invasin (Inv) to α5β1 integrin on Caco-2 cells [1].

LXW7 TFA, a cyclic peptide containing Arg-Gly-Asp (RGD), is an integrin αvβ3 inhibitor with an anti-inflammatory effect. LXW7 has a high binding affinity to αvβ3 integrin (IC50: 0.68 μM). It increases the phosphorylation of VEGFR-2 and activation of ERK1/2.

Cys-Arg-Gly-Asp-Phe-Pro-Ala-Ser-Ser-Cys (Disulfide bridge: Cys1-Cys10), a decapeptide with a cyclic RGD active sequence, functions as an Integrin αIIbβ3 antagonist, effectively inhibiting platelet adhesion and proMMP-13 adhesion [1].

Arg-Gly-Glu-Ser TFA, an RGD-related peptide, serves as a control for evaluating the inhibitory activity of RGDS on fibrinogen binding to activated platelets.

A20FMDV2, a peptide derived from the α-helical RGD cell-interacting domain of the VP1 capsid protein of foot-and-mouth disease virus (FMDV) serotype O, targets and binds αVβ6 integrin. It effectively disrupts αVβ6 integrin-mediated cell adhesion in H357 tongue squamous cell carcinoma cells that exhibit human αVβ6, with an inhibitory concentration (IC50) of 1.2 µM. Additionally, when labeled with 111indium-DTPA, A20FMDV2 (20 MBq) specifically attaches to αVβ6 integrin in a breast cancer mouse xenograft model using MCF10CA1a cells, facilitating targeted radiation imaging analysis.

Certepetide (CEND-1), also known as iRGD, is a bifunctional cyclic peptide that enhances tumor penetration. By interacting with alphav-integrins through its RGD motif and activating NRP-1, it transforms the solid tumor microenvironment into a temporary conduit for therapeutic agents. This property facilitates Certepetide's accumulation in tumors, making it a valuable tool in researching pancreatic cancer and other solid tumors [1] [2] [3].

Arg-gly-glu -Ser(TFA) is a RGD related polypeptide that controls the inhibition of fibrinogen binding to activated platelets by RGDS.

G-{d-Arg}-GDSP, an RGD peptide analogue, binds to the adhesion receptor of integrins, inhibiting cellular attachment to fibronectin and osteoclast resorption [1].

Cyclo(Ala-Arg-Gly-Asp-Mamb) is a selective antagonist of the RGD peptide, with potential applications in pulmonary arterial hypertension research [1].

Arg-Gly-Glu-Ser (RGDS) is an RGD-related peptide used as a control for the activity of fibrinogen binding to activated platelets.